CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

Scientists have revealed how Fanzor2's divergence from bacterial ancestors may make it a useful tool for future genomic engineering endeavors. A revolution in biomedicine is currently underway, driven ...

The discovery of CRISPR-Cas gene editing technology has revolutionized biological research, providing new insights and opportunities for the advancement of several industries. However, the ...

In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches. Precision genome editing technologies have transformed ...

OTTAWA, Nov. 19, 2020 (GLOBE NEWSWIRE) -- One of the most ground-breaking improvements in biology sector has its origins in the RNA-based defense system of bacteria, that encrypts CRISPR-associated ...

The CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) and its associated protein (Cas9) system is a genome-editing technology that holds the potential to alleviate multiple ...

A team of researchers led by Feng Zhang at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT has uncovered the first programmable RNA-guided system in ...

The type I CRISPR protein Cas3 works like Pac-Man, chomping away at a continuous stream of nucleotides with intrinsic activity for introducing targeted large deletions from a few hundred base pairs to ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

Elizabeth Kellogg, PhD, St. Jude Department of Structural Biology, used cryo-EM to study the evolutionary journey of Fanzor2, a compact eukaryotic genome-editing protein with huge potential. (MEMPHIS, ...